Cadila Healthcare Ltd (Zydus Cadila), on Wednesday, said it has received final approval from the USFDA to market Ziprasidone Hydrochloride capsules in the American market.

The drug, in strengths of 20, 40, 60, and 80 mg, is an antipsychotic medication, used to treat schizophrenia and manic symptoms of bipolar disorder (manic depression).

The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad, the company said in a statement here.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.